Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucosacituzumab plus immune checkpoint inhibitor maintenance in ES-SCLC after induction
ChiCTR2500111617Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lucosacituzumab in small cell lung cancer (SCLC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
lucosacituzumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500111617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111617.